Navigation Links
VetStem Biopharma, Inc. Founder and CEO, Dr. Robert Harman, will present a clinical abstract on Allogeneic Adipose Stem Cell Bio-Distribution at the Veterinary Orthopedic
Date:3/8/2017

Dr. Harman has been a long time attendee and frequent speaker at the Veterinary Orthopedic Society Conference. “The opportunity to speak at such a prestigious conference and to present our new data is very exciting. It further reinforces our scientific and educational contributions to the field of regenerative medicine over the past 14 years. We were here at the birth of this industry, have worked with FDA for many years, and intend to provide evidenced-based products for many years to come,” stated Dr. Harman.

The Veterinary Orthopedic Society exists to provide an environment where persons engaged in the practice, teaching, or research in the area of orthopedics can present and discuss items of common interest, to further scientific investigation, and to upgrade the specialty of orthopedics in order to provide better patient care. The conference will be in Snowbird, Utah March 11th through the 18th. Dr. Harman will present VetStem’s findings on the study “Allogeneic Stem Cell Survival and Localization after Intraarticular Administration”. VetStem has a licensing agreement with Aratana Therapeutics for this study. VetStem has always held the belief that scientific evidence, continuing education, and regulatory guidance are the foundation of developing any new technology. The field of veterinary regenerative medicine will progress by the scientific study of the mechanisms of action of stem cells. This particular study evaluated the systemic bio-distribution of allogeneic adipose stem cells following intra-articular administration in beagle dogs.

In 2015, VetStem (now VetStem Biopharma) announced the completion and peer-reviewed publication of a pilot efficacy study for allogeneic stem cell therapy (93 dogs, multi-center, blinded, placebo controlled) in support of an FDA INADA. The primary end point for stem cell treated dogs was statistically significantly improved as compared to placebo dogs. VetStem also entered into a distribution and clinical research agreement with Pall LifeSciences on the V-PETTM platelet enhancement therapy system. The V-PET™ is supported by a JAVMA peer reviewed publication of a two center, double-blinded, randomized study in osteoarthritis in dogs.

VetStem is developing multiple stem cell products for FDA-approval in order to provide therapeutic solutions for difficult-to-treat medical conditions in the dog, cat and horse.

Read the full story at http://www.prweb.com/releases/2017/03/prweb14122829.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Vet-Stem, Inc. Meets New Milestones and Changes Name to VetStem Biopharma
2. VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples
3. Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services.
4. West Coast Bird Dog Champion Wins US Bird Dog Association Western States National Flushing Champion with the help of Stem Cell Therapy by VetStem.
5. Leading Regenerative Veterinary Medicine Company, VetStem Biopharma, Announces the Addition of Dr Ross Rich as the Director of Clinical Development
6. VetStem Biopharma & Veterinary Growth Partners Join Forces to Increase Member Veterinary Hospital Revenue Through Cutting Edge Medical Offering
7. VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities.
8. VetStem Biopharma, proudly announces a new long term partnership with VCA Emergency Animal Hospital & Referral Center.
9. VetStem Biopharma weekly veterinary continuing education classes and GMP manufacturing facility tour
10. VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product
11. VetStem Biopharma, Inc. Founder and CEO, Dr. Robert Harman, to be a Guest Speaker at MSC 2015 Adult Stem Cell Therapy & Regenerative Medicine Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2018)... (PRWEB) , ... July 25, 2018 , ... ... Things (IoT) Systems Innovator, joined the board of the Indiana India Business Council ... and unanimously elected today by the current board of directors, McDonald joins an ...
(Date:7/24/2018)... (PRWEB) , ... July 24, 2018 , ... R3 Stem ... in Las Vegas. The treatments are offered by Double Board Certified providers, with outcomes ... mostly okay with suppressing symptoms, but have done nothing to help repair and regenerate ...
(Date:7/24/2018)... ... July 24, 2018 , ... On August 6, 2018, BioMedGPS ... Not just a pretty face, SmartTRAK 3.0’s latest improvements were inspired by ... the world’s first online and real-time data portal that specializes in providing competitive ...
(Date:7/22/2018)... ... July 19, 2018 , ... Mitotech S.A, a Luxembourg based ... Phase 3 clinical program in Dry Eye Disease. Under the agreement Essex Bio-Investment ... allocated towards the first Phase 3 study starting as early as Fall 2018. ...
Breaking Biology Technology:
(Date:8/9/2018)... ... 2018 , ... Plum Alley Investments, an innovative platform providing ... has invested in a sought-after $23 million Series A round for Mammoth Biosciences ... Biosciences , The biotech company is bringing to market the latest CRISPR innovations ...
(Date:8/7/2018)... ... August 07, 2018 , ... ... development, announces a new publication titled, “Synthetic Molecules for Disruption of the ... paper prominently features use of Agile R100, described as a “ field-effect transistor ...
(Date:8/1/2018)... ... August 01, 2018 , ... Dr. Asher Kimchi, Founder and Chairman of the ... 2018 IAC Awards at the 23rd World Congress on Heart Disease held in Boston, ... to receive the Distinguished Fellowship Awards. , Dr. Asher Kimchi, together with Chairman Dr. ...
Breaking Biology News(10 mins):